Drug intelligence / Profile preview

IPT803

Development stage: Phase 2
Lead developer: Cognivia
Modality: Small Molecules
Administration: Oral

Overview

IPT803 is a novel small molecule drug developed by Tools4Patient for the treatment of Parkinson's disease. It acts as both a dopamine modulator and an opioid receptor antagonist, aiming to improve motor symptoms in patients with Parkinson's disease. The drug has been evaluated as an adjunctive therapy in clinical trials and represents a new molecular entity within the class of antiparkinsonian agents[1][2][3].

Other names: IPT 803IPT803IPT-803

Targets

MOR (Mu opioid receptor)DRD (Dopamine receptors)

Beyond the preview

Go deeper on IPT803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPT803.

Explore the full profile